- Molecular NameAmodiaquine
- SynonymAmodiaquin; Amodiaquine Hydrochloride; Amodiaquine USP24; Amodiaquine, ring-closed
- Weight355.869
- Drugbank_IDDB00613
- ACS_NO86-42-0
- Show 3D model
- LogP (experiment)4.337
- LogP (predicted, AB/LogP v2.0)4.46
- pkaN/A
- LogD (pH=7, predicted)1.76
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-2.44
- LogSw (predicted, AB/LogsW2.0)0.04
- Sw (mg/ml) (predicted, ACD/Labs)0.02
- No.of HBond Donors2
- No.of HBond Acceptors4
- No.of Rotatable Bonds6
- TPSA48.39
- StatusFDA approved
- AdministrationN/A
- PharmacologyA 4-aminoquinoline compound related to chloroquine, used as an antimalarial and anti-inflammatory agent.
- Absorption_valueN/A
- Absorption (description)Amodiaquine is readily absorbed after oral administration and widely distributed throughout the tissues.
- Caco_2N/A
- Bioavailability75.0
- Protein bindingN/A
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmN/A
- Half life5.2 min
- ExcretionAfter absorption it is slowly released into the blood and excreted in the urine for at least 7 days after a single dose; the rate of excretion is increased in acid urine.
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityLD50 (mouse, intraperitoneal) 225 mg/kg, LD50 (mouse, oral) 550 mg/kg. Symptoms of overdose include headache, drowsiness, visual disturbances, vomiting, hypokalaemia, cardiovascular collapse and cardiac and respiratory arrest. Hypotension, if not treated, may progress rapidly to shock. Electrocardiograms (ECG) may reveal atrial standstill, nodal rhythm, prolonged intraventricular conduction time, broadening of the QRS complex, and progressive bradycardia leading to ventricular fibrillation and/or arrest.
- LD50 (rat)N/A
- LD50 (mouse)N/A